In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Serono's Global Ambitions

Executive Summary

Serono, Europe's biggest biotechnology company, is nearly one hundred years old. Recently, the company has been on a quest to establish a public image quite different from that of a traditional, family-owned pharmaceutical group. Driving Serono into the public eye is Ernesto Bertarelli, who took the helm from his father in 1996. The structural changes he brought about provided the framework for modernization. But Serono still has to make its mark in the US, where the most important determinant of success will be the timing of its launch of Rebif, its multiple sclerosis drug.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts